Target: PD-1.
Clone: RMP1-14.
Specificity: Anti-PD-1 In Vivo Antibody - Ultra Low Endotoxin (RMP1-14) recognizes an epitope on Mouse PD-1.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: Subset of double negative thymocytes, activated T and B cells.
Background: CD279, also known as programmed death-1 (PD-1) is a 50-55 kD immunoglobulin superfamily member. PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily. This RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production.
Immunogen: Mouse PD-1 transfected BHK cells.
Concentration: ≥ 2.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.